Análisis del impacto presupuestario de alemtuzumab como terapia de segunda línea, en comparación con natalizumab y fingolimod, en pacientes previamente tratados con interferón beta 1b, diagnosticados con esclerosis múltiple remitente recurrente activa, tratados en la caja costarricense del seguro social
-
Published:2019-01
Issue:
Volume:2019
Page:228424031983328
-
ISSN:2284-2403
-
Container-title:Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish
-
language:en
-
Short-container-title:Global & Regional Health Technology Assessment
Author:
Pastor Quirós Luis1,
Ugalde Rocío1
Publisher
Aboutscience Srl
Reference27 articles.
1. ((“multiple sclerosis”[MeSH Terms] OR (“multiple”[All Fields] AND “sclerosis”[All Fields]) OR “multiple sclerosis”[All Fields]) AND “2006/04/30”[PDat] : “2016/04/26”[PDat]) AND (((“budgets”[MeSH Terms] OR “budgets”[All Fields] OR “budget”[All Fields]) AND impact[All Fields] AND (“analysis”[Subheading] OR “analysis”[All Fields])) AND “2006/04/30”[PDat] : “2016/04/26”[PDat]) AND (“2006/04/30”[PDat] : “2016/04/26”[PDat])
2. Principles of Good Practice for Budget Impact Analysis: Report of the ISPOR Task Force on Good Research Practices—Budget Impact Analysis
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献